Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population

Pharmacogenetics

Volumn 10, Issue 1, 2000, Pages 79-83

  Dhaini, Hassan R ^a   Levy, Gerald N ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Genotyping; Lebanese; N acetyltransferase; NAT1 polymorphism

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CARCINOGEN;

ARTICLE; ETHNIC GROUP; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEBANON; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ACETYLATION; ACETYLTRANSFERASES; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; GENE FREQUENCY; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; ISOENZYMES; LEBANON; MICHIGAN; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0034091891     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200002000-00010     Document Type: Article

References (23)

1. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14:1689-1692.
2. Bouchardy C, Mitrunene K, Wikman H, Husgavfel-Pursianen K, Dayer P, Benhamou S, Hirvonen A. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 1998; 8:291-298.
3. Butcher NJ, Ilett KF, Minchin RF. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. Pharmacogenetics 1998; 8:67-72.
4. Cartwright RA, Ahmad RA, Rogers HJ. N-Acetyltransferase phenotypes in Iraqi and British populations. Hum Hered 1984; 34:101-104.
5. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetylation (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57:581-592.
6. Deitz AC, Doll MA, Hein DW. A restriction fragment polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal Biochem 1997; 253:219-224.
7. Evans DAP, Paterson S, Francisco P, Alvarez G. The acetylator phenotypes of Saudi Arabian diabetics. J Med Genet 1985; 22:479-483.
8. Hayney MS, Dimanlig P, Lipsky JJ, Poland GA. Utility of a 'swish and spit' technique for the collection of buccal cells for TAP haplotype determination. Mayo Clin Proc 1995; 70:951-954.
9. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochem Biophys Acta 1988; 948:37-66.
10. Hughes NC, Janezic SA, McQueen KL, Jewett MAS, Castranio T, Bell DA, Grant DM. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998; 8:55-66.
11. Irshaid Y, al-Hadidi H, Abuirjeie M, Latif A, Sartawi O, Rawashdeh N. Acetylator phenotypes of Jordanian diabetics. Eur J Clin Pharmacol 1992; 43:621-623.
12. Karim AKMB, Elfellah MS, Evans DAP. Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distribution. J Med Genet 1981; 18:325-333.
13. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994; 4:125-134.
14. Lin HJ, Probst-Hensch NM, Hughes NC, Sakamoto GT, Louie AD, Kau IH, et al. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenoma. Pharmacogenetics 1998; 8:269-281.
15. Matas N, Thygesen P, Stacey M, Risch A, Sim E. Mapping AAC1, AAC2, and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolizing enzymes on human chromosome 8p22, a region frequently deleted in tumors. Cytogen Cell Genet 1997; 77:290-295.
16. Probst-Hensch NM, Haile RH, Ingles SA, Longnecker MP, Han CY, Lin BK, et al. Acetylation polymorphism and prevalence of colorectal adenomas. Cancer Res 1995; 55:2017-2020.
17. Smith CAD, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 1997; 34:758-760.
18. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, et al. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 1998; 58:3603-3610.
19. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 1993; 301:71-76.
20. Vatsis KP, Weber WW, Bell DA, Dupret JM. Evans DAP, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5:1-9.
21. Weber WW. The acetylator genes and drug response. New York: Oxford University Press; 1987.
22. Zhao B, Lee EJD, Yeoh PN, Gong NH. Detection of mutations and polymorphisms of N-acetyltransferase 1 gene in Indian, Malay, and Chinese populations. Pharmacogenetics 1998; 8:299-304.
23. Zheng W, Deitz AC, Campbell DR, Wen W-Q, Cerhan JR, Sellers TA, et al. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8:233-239.